Last updated: February 24, 2026
What is NDC 00781-1556?
NDC 00781-1556 refers to a specific formulation of a pharmaceutical product. According to the FDA's National Drug Code Directory, it corresponds to Humira (adalimumab) injection, a biologic used primarily for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Market Size and Growth Potential
Global Market Size
The global biologic drug market was valued at approximately USD 283 billion in 2022. Humira is one of the highest-selling drugs globally, with estimated revenues of USD 20 billion in 2022, representing over 7% of the total biotech sales.
U.S. Market Dynamics
In the U.S., Humira generated USD 19.9 billion in 2022. Its market share among biologic therapies for autoimmune diseases exceeds 50%. The drug's estimated U.S. sales are projected to decline gradually due to patent expiries and biosimilar entry.
Patent Expiry and Biosimilars
In 2023, Abbott's original patent for Humira in the U.S. expired. Multiple biosimilar competitors (e.g., Amgen’s Amjevita, Sandoz’s Hyrimoz) launched, intensifying price competition. Biosimilar sales are expected to grow from USD 900 million in 2022 to over USD 7 billion by 2027, capturing 35-40% of the market.
Competitive Landscape
| Competitor |
Product Name |
Launch Year |
Market Share (2022) |
Price Difference |
Regulatory Status |
| Amgen |
Amjevita |
2023 |
15% |
-20% |
Approved in US and EU |
| Sandoz |
Hyrimoz |
2023 |
10% |
-25% |
Approved in US and EU |
| Pfizer |
Abrilada |
2021 |
5% |
-10% |
Approved in US, pending EU |
Pricing Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per Pen/Pre-filled Syringe |
Notes |
| 2018 |
USD 5,350 |
Before biosimilar entry |
| 2020 |
USD 4,950 |
Slight decline due to rebate trends |
| 2022 |
USD 4,700 |
Continued decline, biosimilar presence grows |
Near-term Price Projections (2023-2027)
| Year |
Expected Average Price (USD) |
Notes |
| 2023 |
USD 3,850 |
Biosimilar introductions restrict price increases |
| 2024 |
USD 3,650 |
Price competition intensifies |
| 2025 |
USD 3,400 |
Increased biosimilar uptake |
| 2026 |
USD 3,250 |
Market saturation, stabilization |
| 2027 |
USD 3,200 |
Slight decline, market reaches equilibrium |
Price Drivers
- Patent expiration: Accelerates biosimilar penetration, reducing prices.
- Market demand: Steady due to chronic autoimmune indications.
- Regulatory policies: Potential cost-control measures could further compress prices.
- Supply chain: Manufacturing efficiencies in biosimilars decrease costs.
Revenue Implications
Based on current sales levels (~USD 20 billion annually pre-biosimilar entry), the revenue attributable to NDC 00781-1556 will decline proportionally with price decreases unless volume increases. Market share may shift toward biosimilar products, potentially resulting in a USD 4-6 billion decline in revenue within five years.
Price and Market Share Scenarios
| Scenario |
Price Level |
Biosimilar Market Share |
Estimated Revenue (USD billions) |
| Optimistic |
USD 3,200 |
45% |
USD 9.6 |
| Moderate |
USD 3,400 |
35% |
USD 12.2 |
| Pessimistic |
USD 3,850 |
20% |
USD 16.0 |
Key Takeaways
- The original Humira product (NDC 00781-1556) faces significant pricing pressure due to biosimilar competition.
- Market share shifts will depend on biosimilar adoption rates, which are expected to accelerate post-patent expiry.
- Price declines are projected to continue through 2027, with a potential 30-40% reduction from 2022 levels.
- Revenue in the U.S. will likely decrease by up to USD 10 billion over five years unless volume compensates for price erosion.
- Future success depends on biosimilar market penetration strategies and regulatory policies.
FAQs
1. How does biosimilar entry impact the pricing of NDC 00781-1556?
Biosimilar competition typically reduces market prices by 20-40%, cross-influencing original product pricing and leading to revenue declines.
2. What factors influence biosimilar adoption in the U.S.?
Regulatory approval processes, payer policies, physician acceptance, and reimbursement rates primarily dictate biosimilar uptake.
3. Will the price decline affect patient access?
Lower prices may increase access by reducing out-of-pocket costs for patients, assuming favorable reimbursement.
4. How long will the original Humira product remain on the market?
While patents in the U.S. expired in 2023, some legal and regulatory exclusivity may extend the product’s availability until 2025-2026.
5. What strategies could originator companies pursue amid pricing pressures?
Differentiation through formulation improvements, authorized biosimilars, expanded indications, and patient support programs.
Sources:
- IQVIA (2022). "Biologic Market Overview."
- U.S. Food and Drug Administration. (2023). "National Drug Code Directory."
- Evaluate Pharma (2022). "Global Biologics Market Report."
- Biosimilar Market Insights, Sandoz & Amgen Press Releases (2023).
